Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the
coronavirus disease 2019 (COVID-19) pandemic that emerged in December 2019 in Wuhan …

The emergence of a novel human coronavirus, severe acute respiratory syndrome
coronavirus 2 (SARS‐CoV‐2), has engaged considerable awareness and attention around …

Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been
demonstrated to be clinically useful against COVID-19 (refs.,). However, because SARS …

Efforts to determine why new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) variants demonstrate improved fitness have been limited to analyzing mutations in the …

Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first
protease inhibitor specifically developed against the SARS-CoV-2 protease 3CLpro that has …

The recent emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
2), the underlying cause of Coronavirus Disease 2019 (COVID-19), has led to a worldwide …

One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being rolled out under emergency use authorizations. It is of great concern that newly …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the viral pathogen
responsible for the current coronavirus disease 2019 (COVID-19) pandemic. As of 19 May …

Nirmatrelvir is a specific antiviral drug that targets the main protease (Mpro) of SARS-CoV-2
and has been approved to treat COVID-19,. As an RNA virus characterized by high mutation …

Summary The SARS-CoV-2 3CL protease (3CL pro) is an attractive therapeutic target, as it
is essential to the virus and highly conserved among coronaviruses. However, our current …